Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth strategy. The vast majority of the company’s revenue is generated in Italy, followed by France and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company’s profit is derived from its specialty and primary care segment, which includes the production of active ingredients.